Syngene offers contract research, development and manufacturing services for biopharmaceutical and other relevant industries.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
Syngene International is a contract research, development and manufacturing organisation (CRDMO) serving the global pharmaceutical, biotech, nutrition, animal health, consumer goods and speciality chemical sectors.
We aim to build strategic, long-term relationships with our clients and partners by offering a range of research and development services, from initial research programme planning to candidate selection, pre-clinical and clinical development, and manufacturing.
Syngene operates world-class facilities for discovery, development and manufacturing activities, covering a total of two million square feet.
Our state-of-the-art research facilities are certified according to ISO 9001: 2008, ISO 14001: 2004 and OHSAS 18001: 2007 standards. Our animal facilities are good laboratory practice (GLP) certified by Indian authorities and accredited by the American Association for Accreditation of Laboratory Animal Care (AAALAC). Syngene is also India’s only GLP viral clearance service provider as certified by the Indian Government’s National GLP Compliance Monitoring Authority.
Our labs are certified by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Product Development and Management Association (PDMA).
A strong corporate governance framework focused on client satisfaction, quality, safety, ethics and integrity makes us the partner of choice for all research-related services. We currently have more than 400 active clients worldwide and hold more than 400 patents with clients.
Syngene is an innovation-led CRDMO offering both standalone and integrated scientific services, from early discovery to commercial supply, for therapeutics of all sizes. We serve biotechnology companies, non-profit institutions, academic centres and government organisations.
We help leading pharmaceutical and biotechnology companies navigate regulatory requirements and get their products to market more quickly. We apply our scientific expertise to deliver innovation in segments beyond life sciences, including speciality chemicals and consumer products.
Syngene provides high-quality, customised and cost-effective services that comply fully with regulatory standards, no matter the scale or scope of the client’s project. Our discovery services cover early-stage research, from target identification to delivering drug candidates for further development.
Syngene’s development services encompass activities from pre-clinical to clinical trials, including drug substance development, drug product development, and other associated services to demonstrate the selected drug candidate’s safety, tolerability, and efficacy.
Our manufacturing services for small molecules and biologics include current good manufacturing practice (cGMP) compliant facilities for clinical supplies, registration batches and commercial volumes through our active pharmaceutical ingredient (API) manufacturing plant and disposable biologics manufacturing facility.
Syngene operates dedicated research and development (R&D) facilities for strategic clients, providing exclusive access to research teams, infrastructure, and project management to support our clients’ R&D requirements.
Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene’s more than 6,000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation.
Syngene provides a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb, as well as specialist discovery, development, and manufacturing facilities covering 2.2 million square feet in total. We work with biotech companies pursuing leading-edge science in addition to multinationals, including GSK, Zoetis and Merck KGaA. Syngene USA is our wholly owned US-based subsidiary.
In this white paper, we discuss the typical supply chain challenges faced by global CROs and CDMOs. You will also learn how Syngene, a leading CRO-CDMO for small and large molecules, has transformed its supply chain to mitigate these risks and turned them into a competitive advantage.
To gain insight into perceptions of differing outsourcing strategies, Syngene and Pharma Intelligence surveyed industry leaders about their experiences. This free white paper analyses the results of the survey.
Biophysics-driven understanding of higher order structures (HOS) and corresponding critical quality attributes (CQA) are imperative for drug regulation.
Enhanced productivity of target protein is the requirement of any industry, and more so in the biopharma industry, wherein the productivity cost is high.
Detection and quantitation of process-related impurities is an important part of quality control in biopharma manufacturing. Process-related impurities can significantly impact a pharmaceutical product's quality, safety and efficacy.
PROteolysis TArgeting Chimeras (PROTACs) have garnered a lot of attention in recent times for their ability to exploit the cell's own degradation machinery to irreversibly degrade target proteins.
AI helps identify better targets and candidates for drug development faster by utilising large datasets of biological and chemical information and applying machine learning algorithms to analyse the data.
¡Saludos! Welcome to the ultimate guide to experiencing Barcelona’s charm and culture, tailored exclusively for attendees of CPHI Barcelona 24 to 26 October 2023.
When you select Syngene for your biologics programme, you partner with a 30-year industry leader solving complex R&D and manufacturing challenges. With our highly experienced team, state-of-the-art infrastructure, proven track record and a portfolio of product experience, we help you navigate the complex journey from discovery to commercial supply.
Syngene International, a leading global CRDMO, is set to participate in DCAT Week 2025, taking place from 17–20 March in New York City. As a strategic partner to global pharmaceutical and biotechnology companies, Syngene will showcase its end-to-end small molecule and biologics CDMO solutions. Our solutions are designed to drive efficiency and innovation resulting in accelerated timelines, from early-stage development to commercial manufacturing.
Syngene International, a leading global CRDMO, is excited to announce its participation in the Animal Health, Nutrition, and Technology Innovation (AHNTI) Event 2025, taking place from 10-12 February at Intercontinental London – O2 in London, UK.
Syngene International, a global integrated research, development, and manufacturing services company, will be exhibiting at CPHI Worldwide 2024 in Milan, Italy, at Booth #7C114, from 8-10 October.
Leading contract research, development and manufacturing organisation Syngene International (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is participating as exhibitor at the Bio International Convention, San Diego, between 3-6 June 2024.
Syngene International (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), a leading integrated contract research, development, and manufacturing organisation, announces its participation as an exhibitor at CPHI North America 2024, held at the Pennsylvania Convention Center, Philadelphia, from 7-9 May 2024.
Syngene is excited to announce its participation in CPHI Japan 2024. The event will be held at Tokyo Big Sight from 17-19 April 2024.
Syngene is thrilled to announce its participation in the upcoming Festival of Biologics, scheduled from 15-17 April 2024 in San Diego, California.
The much-anticipated Drug, Chemical & Associated Technologies (DCAT) Week in New York City is around the corner, and Syngene is excited to be participating.
Syngene International, a global leader in contract research, development and manufacturing services, continues its trajectory of growth and innovation with significant developments in recent months.
Syngene is participating in BioAsia 2024 between 26-28 Feb 2024 in Hyderabad.
Syngene International announced on 17 October its second quarter and half-year financial results. Reported revenue from operations for the quarter was up 18.5% year-on-year to Rs9.1bn, around 15% at constant currency. Profit after tax (before exceptional items) for the quarter increased 20% year-on-year to Rs1.22bn.
Syngene International Limited, a leading global contract research, development, and manufacturing services organization, announced the purchase of a 17-acre land parcel in Genome Valley, Hyderabad as an extension to its existing research campus. Construction of the new facilities will begin in 2024, following the necessary statutory approvals.
Syngene International today announced the signing of a ten-year agreement with leading animal health company, Zoetis, to manufacture the drug substance for Librela® (bedinvetmab), a first-in-class monoclonal antibody used for treating osteoarthritis in dogs. Launched in Europe, the UK and Switzerland, the product won ‘Best new companion animal product’ by IHS Markit Connect in 2021 for its transformational impact on pain relief for canines suffering from this debilitating condition.
Current customers rate company top in all categories: quality, expertise, compatibility, capabilities, reliability and service.
Syngene International and Deerfield Discovery and Development Corporation (3DC) have signed an agreement to collaborate to advance therapeutic discovery projects.
The collaboration has been extended through the end of 2030 and will expand the breadth of drug discovery research conducted.
Syngene provides comprehensive process research and development services as well as current good manufacturing practices (cGMP) manufacturing capacities to help clients with investigational to commercial-scale development programs.
Syngene offers formulation development services to help clients determine optimal dosage levels for therapeutic formulations in oral solid, liquid, and injectable forms. Our integrated services extend to new chemical entities (NCE), late-phase product development, and over-the-counter products with a focus on quality, speed, and cost-efficiency.
Syngene’s analytical development services team analyses small and large molecules using a variety of spectroscopic, chromatographic, and physiochemical techniques.
Syngene’s clinical development services team enables early-phase to late-phase clinical trials required for drug development programs across a wide range of therapeutic areas.
Syngene is at the Heart of Biologics, offering integrated services across the drug discovery, development and manufacturing continuum. As a fully integrated custom biomanufacturer, our solutions include mammalian and microbial capabilities for clinical and commercial supplies.
We are an innovation-led, contract research, development & manufacturing organization offering integrated scientific services from early discovery to commercial supply.
State-of-the-art multi-product, multi-client contract manufacturing facility located at Mangalore Special Economic Zone (MSEZ) spread across a sprawling 46 acre campus. Plant designed to support large-scale API and advanced intermediate manufacturing
This video gives an overview of Syngene's manufacturing plant in Mangalore, India, outlining its statistics and capabilities.
Part One of an interview with Jayadeva Sajankila, who has been working at Syngene for 21 years and is currently part of the company's Chemical Development Operations unit.
Part Two of an interview with Jayadeva Sajankila, who has been working at Syngene for 21 years and is currently part of the company's Chemical Development Operations unit.
This video gives an overview of Syngene's large molecule bioanalytical facility, which supplies immnunoassays for a range of applications.
A video outlining the statistics and capabilities of Syngene's sterile fill/finish facility.
